

4th International Conference and Exhibition on **Cell & Gene Therapy**

August 10-12, 2015 London, UK

GSH -responsive nanoparticles in the treatment of tumor cells

Stefania Pizzimenti
University of Turin, Italy

Cancer cells which develop resistance toward chemotherapeutic drugs become highly adapted to intrinsic oxidative stress by up-regulating their antioxidant systems which in turn can increase their capacity for drug inactivation. The major player in oxidative adaptation of cancer cells is glutathione (GSH). Doxorubicin is one of the most widely used drugs for treatment of cancers which acts by poisoning Topoisomerase-II by forming adducts with DNA and by inducing oxidative stress. However, doxorubicin use is limited by cardiac and kidney toxicity and by drug resistance. We have recently developed a new class of cyclodextrin nano sponges that are GSH-responsive (GSH-NSs) and able to release anticancer drugs in the presence of high GSH concentrations similar to those detected in cancer chemo-resistant cells. In the present paper, we loaded GSH-NSs with doxorubicin and tested its toxic effect in cells with various GSH concentrations. The obtained results demonstrated that doxorubicin loaded GSH-NSs inhibited cell viability and topoisomerase activity and induced DNA damage with higher effectiveness than free drug in the cells with high GSH content whereas in the cells with low GSH-content their action was similar to that displayed by the free drug. Furthermore, GSH-NSs, loaded with low doses of doxorubicin inhibited clonogenic growth more than free doxorubicin, thus allowing the reduction of the effective doses. These characteristics indicate that GSH-NSs can be a suitable drug delivery carrier for future applications in cancer therapy.

Biography

Stefania Pizzimenti has completed her PhD in Experimental and Molecular Pathology and Post graduate degree in Clinical Pathology at the University of Torino, Italy. She was Visiting Fellow at the Institute for Molecular Biology and Tumor Research, Philipps-University of Marburg, Germany and at the Institute of General Pathology, University of Milano, Italy. Since 2008, she is an Assistant Professor at the University of Torino. She is the author of more than 40 papers in reputed journals and Editorial Board Member of several journals like "SM Journal of Nanotechnology and Nanomedicine", "Journal of Pediatric Oncology" and "ISRN Cell Biology".

Notes: